PDE10A Inhibitor MK-8189 Fails Phase 2b Schizophrenia Trial
Mukai et al.’s 499-person Phase 2b schizophrenia trial tested whether higher, sustained PDE10A inhibition could turn MK-8189 into a non-D2 antipsychotic; it did not. At week 6, MK-8189 misse…
Read article